Document Detail

Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies.
Jump to Full Text
MedLine Citation:
PMID:  21814473     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Neurodegenerative diseases are a common late-life scourge for which disease-modifying treatments are sorely needed. Mitochondrial perturbation is commonly observed in these diseases, so pursuing treatment development strategies that target mitochondria or processes affected by mitochondria seems reasonable. This review discusses the rationale underlying past and current efforts to treat neurodegenerative diseases using mitochondrial medicine, and tries to predict how future efforts might proceed.
Authors:
Russell H Swerdlow
Related Documents :
15235683 - The role of the putative virulence markers (caga and vaca ) of helicobacter pylori in p...
11148003 - Emergence of diverse helicobacter species in the pathogenesis of gastric and enterohepa...
19829313 - Chronic kidney disease and vitamin d: how much is adequate?
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Pharmaceuticals (Basel, Switzerland)     Volume:  2     ISSN:  1424-8247     ISO Abbreviation:  -     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2011-8-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101238453     Medline TA:  Pharmaceuticals (Basel)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  150-167     Citation Subset:  -    
Affiliation:
Departments of Neurology and Molecular and Integrative Physiology, University of Kansas School of Medicine, Kansas City, MO, Kansas 66160, USA; Tel.: +1-913-588-0685;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Grant Support
ID/Acronym/Agency:
R01 AG022407-04//NIA NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Pharmaceuticals (Basel)
Journal ID (iso-abbrev): Pharmaceuticals (Basel)
Journal ID (publisher-id): pharmaceuticals
ISSN: 1424-8247
Publisher: Molecular Diversity Preservation International
Article Information
Download PDF
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.
open-access:
Received Day: 19 Month: 11 Year: 2009
Revision Received Day: 27 Month: 11 Year: 2009
Accepted Day: 02 Month: 12 Year: 2009
Electronic publication date: Day: 03 Month: 12 Year: 2009
collection publication date: Month: 12 Year: 2009
Volume: 2 Issue: 3
First Page: 150 Last Page: 167
PubMed Id: 21814473
ID: 3148068
DOI: 10.3390/ph2030150
Publisher Id: pharmaceuticals-02-00150

Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies
Russell H. Swerdlow
Departments of Neurology and Molecular and Integrative Physiology, University of Kansas School of Medicine, Kansas City, MO, Kansas 66160, USA; Email: rswerdlow@kumc.edu; Tel.: +1-913-588-0685; Fax: +1-913-588-0681.

1. Neurodegenerative Diseases Are Mitochondriopathies
1.1. Brief overview of the neurodegenerative diseases

Neurodegenerative diseases are characterized by the progressive loss of neuron populations. These disorders afflict all age groups. There are rare childhood neurodegenerations, neurodegenerations that present in early or mid-adulthood, and others that manifest in late-life. The latter neurodegenerations are particularly common. A case can be made that among the oldest old it is more common to have a neurodegenerative disease than it is to not have one [1].

Individual neurodegenerative diseases are defined on both clinical and pathological levels. Diagnoses are most reliable when a specific, recognizable clinical syndrome occurs in conjunction with specific brain histopathology. Diagnostic limitations arise from the fact that substantial clinical overlap exists between some disorders, clinical presentations are occasionally atypical or simply hard to characterize, and various pathologic features may co-exist in the brains of affected patients. The neurodegenerative disorder dementia with Lewy bodies (DLB) is a straightforward example of this. Dementia is a central feature of DLB, and parkinsonism is a frequently cited core feature [2]. Patients diagnosed with DLB often fulfill clinical criteria for both Alzheimer’s disease (AD) and Parkinson’s disease (PD). Their brains also show neuritic plaques and neurofibrillary tangles, findings typically associated with AD, as well as Lewy bodies, which are typically associated with PD.

In addition to clinical and pathology overlap, molecular overlap also occurs. One recurrent theme is protein aggregation. Protein aggregation can occur extracellularly, in the cytosol, in the nucleus, or in combination. Amyloid plaques are examples of extracellular protein aggregation. In AD, plaques contain the beta amyloid (Aβ) protein, which is itself produced through the enzymatic digestion of the larger amyloid precursor protein (APP). Diseases with amyloid aggregation qualify as “amyloidoses”.

Tau, tar binding protein 43 (TDP43), and synuclein form cytosolic aggregations. Tau comprises the “tangles” seen in multiple neurodegenerative diseases including AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). TDP43 aggregation occurs in FTD and amyotrophic lateral sclerosis (ALS). Synuclein, the primary constituent of Lewy bodies, aggregates in PD, DLB, and muti-system atrophy (MSA). Synuclein is also found extracellularly in AD plaques. These disorders may be variably classified as “tauopathies”, “TDP43-opathies”, and “synucleinopathies”. Nuclear aggregations can occur in neurodegenerative diseases caused by triple repeat expansions. For example, in Hungtington’s disease (HD), huntingtin protein (htt) aggregates in neuron nuclei.

Another recurrent molecular theme in neurodegenerative diseases is mitochondrial perturbation. Observed mitochondrial perturbations are believed to associate with mitochondrial dysfunction. The role mitochondrial perturbation plays in neurodegenerative diseases is sometimes unclear and may differ from disease to disease. In some disorders it appears to initiate neuronal dysfunction and ultimately degeneration. In others it possibly plays an intermediary but unique contributory role. Occasionally, it may represent a generic but still important consequence of more upstream cascades. The term “neurodegenerative mitochondriopathies” was previously proposed to categorize neurodegenerative diseases that feature mitochondrial perturbation [3,4]. The following section provides a brief overview of mitochondrial defects seen in various neurodegenerative diseases.

1.2. Mitochondrial perturbation occurs in multiple neurodegenerative diseases

In general, mitochondrial perturbation can arise in several ways. Mutations in mitochondrial DNA (mtDNA) genes, mutations in nuclear genes encoding mitochondrial proteins, and defects in intergenomic signaling can all interfere with mitochondrial function. Gain of function mutations in proteins that normally have no or limited mitochondrial interaction may cause them to directly or indirectly hinder mitochondrial function. Loss of function mutations may deprive mitochondria of necessary support. Changes in the cytosolic milieu may also disrupt mitochondria. Functional defects may involve transport of proteins and substrates into and out of the mitochondria, or else substrate utilization. Mitochondrial perturbations may be fairly non-specific or specific. Examples of non-specific changes include mitochondrial depolarization, enlargement, and ultrastructure changes. Examples of specific defects include diseases in which one but not other respiratory enzymes have altered function.

Both specific and non-specific mitochondrial perturbations are observed in AD [5]. The most specific defect involves a reduction in the complex IV (cytochrome oxidase) Vmax activity [6]. This defect is seen in brains and non-degenerating tissues of AD patients. Most studies suggest Vmax activities of other electron transport chain (ETC) enzymes are normal. When mitochondria from AD or control subject platelets are transferred to mtDNA-depleted, respiratory-incompetent cells to form cytoplasmic hybrid (cybrid) cell lines, respiratory function is restored but the cytochrome oxidase Vmax activity in cybrid lines containing AD subject mtDNA is less than it is in cyrid lines containing control subject mtDNA [7,8,9]. This suggests the AD cytochrome oxidase defect arises from mtDNA, although the exact AD mtDNA problem is unclear. Other forms of AD mitochondrial dysfunction are documented, including reductions in the pyruvate dehydrogenase complex Vmax and the ketoglutarate dehydrogenase Vmax [5]. Oxidative stress is increased in AD subject tissues, and may reflect mitochondrial dysfunction. AD brains also show altered mitochdondrial ultrastructure, increased levels of the 5 KB “common” mtDNA deletion, reduced numbers of intact mitochondria, increased numbers of degrading mitochondria, and altered mitochondrial fission-fusion dynamics [10,11].

From a cause-and-effect perspective AD is particularly perplexing because more than one type of AD may exist [1]. Rare autosomal dominant cases that arise from APP mutations can be modeled in genetically altered mice via overexpression of a mutated human APP transgene (tg2576 mice). Mitochondrial physiology is altered in these mice. One early change indicates mitochondrial proliferation, which suggests expression of the mutant transgene negatively impacts mitochondrial performance and induces a compensatory response [12]. Similar results were more recently reported from triple transgenic mice that also express mutant presenilin 1 and tau transgenes [13]. Other studies indicate in tg2576 mice Aβ interferes with the mitochondrial permeability transition as well as the function of the mitochondrial abeta-binding alcohol dehydrogenase (ABAD) enzyme [14,15]. In humans, APP is found in the mitochondrial membrane and Aβ is found inside the mitochondria [16,17,18]. However, it has also been shown that mitochondrial dysfunction can increase Aβ production [19,20]. Some propose that in sporadic, late onset AD upstream mitochondrial dysfunction may account for a downstream amyloidosis [21,22].

PD also is characterized by specific and non-specific mitochondrial perturbations. Complex I activity is consistently found to be reduced both in the brains and peripheral tissues of PD patients, while activities of other ETC enzymes are generally not [4,23,24]. The PD complex I defect is believed to be particularly relevant since complex I inhibition produces parkinsonism and dopaminergic neurons appear particularly vulnerable to complex I inhibition [25,26]. Similar to what is seen in AD, when mitochondria from PD subject platelets are used to produce cybrid cell lines, respiratory function is restored but the complex I Vmax activity is less than in cybrid lines containing control subject mtDNA [7,27,28,29]. This suggests the PD complex I defect arises from mtDNA. Although the exact PD mtDNA problem is unclear, PD subject substantia nigra neurons have increased levels of mtDNA deletions and their brains show microheteroplasmic mutations in specific stretches of the mtDNA ND5 gene [30,31,32,33]. Oxidative stress markers are elevated in PD subject tissues, and cybrid studies further suggest this arises as a consequence of complex I dysfunction [7,27,34].

PD, like AD, is etiologically heterogeneous with at least one common sporadic form and a number of rare Mendelian forms. Mutations that cause several of the Mendelian forms affect proteins that either localize to mitochondria or otherwise appear to influence mitochondrial function [35].

Other sporadic neurodegenerative diseases are associated with specific ETC Vmax reductions. Amyotrophic lateral sclerosis is most generally associated with complex I dysfunction, although reduced cytochrome oxidase Vmax activities are occasionally reported [36,37]. PSP cybrids have a complex I Vmax defect, which suggests PSP subjects should themselves have reduced complex I activity [38,39]. Oxidative stress is increased in both these diseases. Mitochondrial dysfunction is also implicated in numerous Mendelian neurodegenerations. Multiple ETC Vmax activities are reportedly reduced in HD [40]. It is unclear whether htt mutation disrupts mitochondrial function by directly interacting with the organelles themselves, or indirectly by affecting other proteins or genes that impact mitochondrial function [41,42]. Frataxin, the mutated gene that causes Friedreich’s ataxia (FA), encodes a protein that plays a role in mitochondrial iron homeostasis [43,44].

Neurodegeneration occurs in various mitochondrial encephalomyopathy disorders that are caused by specific mtDNA mutations [4]. The mitochondrial encephalomyopathies tend to occur in childhood or early adulthood. One of the best characterized mtDNA diseases is Leber’s hereditary optic neuropathy (LHON), a neuroanatomically discrete neurodegenerative disease of the optic nerve.

The list of neurodegenerative mitochondriopathies is long and these disorders are more comprehensively described elsewhere [4]. Even from this brief overview, though, it is clear that mitochondrial perturbation is a common theme in neurodegenerative diseases. For disorders that qualify as neurodegenerative mitochondriopathies, pursuing treatment development strategies that target mitochondria or processes affected by mitochondria seems reasonable [3].


2. Mitochondrial Medicine
2.1. Definition and overview of mitochondrial medicine targets

“Mitochondrial medicine” describes efforts to directly manage mitochondrial dysfunction as well as attempts to directly or indirectly manage its consequences [45]. Early on, the well-recognized role of mitochondria in energy production gave rise to strategies designed to enhance electron transfer through the ETC. More recently, extensive mitochondrial integration within programmed cell death programs was demonstrated [46]. Attempts to abort programmed cell death cascades by blocking this integration are in vogue. Finally, oxidative stress is seen in many neurodegenerative diseases. Since oxidative stress may either arise as a consequence of mitochondrial dysfunction or else interfere with mitochondrial function, reducing oxidative stress qualifies as a form of mitochondrial medicine.

Figure 1 provides an overview of pathways featured in energy production. Attempts to directly manage mitochondrial dysfunction by increasing energy production have traditionally included B vitamin supplements, since some B vitamins (riboflavin, or B2; niacin, or B3) are used to generate molecules that donate electrons to the mitochondrial respiratory chain. Other B vitamins (thiamine, or B1) are cofactors in biochemical reactions that generate bioenergetic pathway intermediates such as acetyl CoA. Thiamine, lipoic acid, and dichloroacetate have been used to enhance pyruvate dehydrogenase activity and increase acetyl CoA levels. Molecules capable of accepting electrons from or donating electrons to the respiratory chain (coenzyme Q, idebenone, vitamin K derivatives, methylene blue) have been used with the intent of augmenting reduced electron transport through the respiratory chain.

Other approaches for enhancing cell energy supplies have been considered. Using acetyl donors like acetyl carnitine to increase Krebs cycle carbon flux is one approach [47,48]. Using the ketone body betahydroxybutyrate to encourage carbon entry into the Krebs cycle is another [49]. More indirect ways of buttressing cell energy reserves include administering compounds such as creatine that can store high energy phosphate bonds [50].

Neurodegenerative cell demise may occur via programmed cell death pathways [46]. These pathways are activated when mitochondria release proteins normally sequestered within them. Examples include cytochrome c, apoptosis initiating factor (AIF), and SMAC/DIABLO [51]. Release reportedly is mediated by or at least associated with the formation of an inner and outer mitochondrial membrane pore. To accomplish this “mitochondrial permeability transition” (MPT), the voltage dependent anion channel (VDAC; also called porin) protein of the outer mitochondrial membrane associates with the adenine nucleotide transporter (ANT) protein of the inner mitochondrial membrane [52,53]. This process depends on cyclophilin D, an intermembrane space protein that is also a requisite MPT component. Agents that can block the MPT or interfere with formation of the MPT pore, such as cyclosporine and minocycline, have been considered for the treatment of neurodegenerative diseases.

Because defective mitochondria produce elevated amounts of reactive oxygen species (ROS), which causes oxidative stress, antioxidants have also been advocated for the treatment of mitochondrial dysfunction. Drugs used for their antioxidant potential include not only vitamin C, vitamin E, and β-carotene but also several of the electron acceptors already mentioned such as coenzyme Q and idebenone.

2.2. Past and current experience

ETC enhancement was initially attempted in encephalomyopathy patients [3,54]. Reported outcomes vary. Case reports and case series typically report some degree of success. While the low prevalence of these disorders makes it difficult to conduct definitive controlled trials, in general the controlled trials that have been done failed to show clinical benefits.

Using creatine to facilitate energy storage has been or is being tried in ALS, HD, and PD [3]. ALS subjects did not show demonstrable benefits. Although some trials of creatine in HD have suggested a small degree of efficacy, most have not [50]. Clinical studies of creatine in HD are still ongoing but a recent review of all available data concluded it probably does not help in HD [55]. A large study of creatinine in PD is currently underway.

Mitochondrial medicine for the treatment of AD was advocated even before the AD cytochrome oxidase defect was discovered. In 1989, Swerdlow et al. reported AD brains can metabolize β-hydroxybutyrate and proposed using ketone bodies to treat AD [56]. At that time it was known AD brains had reduced glucose consumption. Because β-hydroxybutyrate negotiates the blood-brain barrier, accesses neuron mitochondria, produces acetyl CoA, and supplies acetyl groups to the Krebs cycle Swerdlow et al. concluded β-hydroxybutyrate could potentially provide an alternative to and mitigate the consequences of reduced AD brain glucose consumption [56]. Two decades later, the Food and Drug Administration ruled that the compound AC-1202 (ketasyn) could be marketed as a medical food for the treatment of AD. Ketasyn, a medium chain triglyceride, is converted by the liver to β-hydroxybutyrate and increases serum β-hydroxybutyrate levels in the absence of other dietary manipulations such as fasting or carbohydrate restriction. A double-blind, placebo-controlled trial of ketasyn in AD subjects was reported in 2009 [57]. Subjects underwent cognitive testing 45 and 90 days after starting in the study. APOE4-negative subjects receiving ketasyn performed better than those receiving placebo; for APOE4 carriers day 45 and 90 cognitive performances were comparable. For several reasons it is difficult to draw firm conclusions from this trial, but in general the possibility that some AD subjects did benefit from ketasyn cannot be excluded.

Coenzyme Q has been considered for neurodegenerative disease treatment based on its known participation in ETC function and its ability to act as antioxidant. An initial phase II trial of coenzyme Q in PD reported slowed progression, but no further supportive data have emerged since this trial [58]. Idebonone, a water soluble coenzyme Q analog, benefited cardiac hypertrophy in FA but had no impact on its neurologic signs and symptoms [59,60]. A small pilot study suggested coenzyme Q might potentially benefit PSP patients to a slight degree [61].

Antioxidants have been evaluated in retrospective epidemiologic studies, prospective epidemiologic studies, and actual clinical trials. Some epidemiologic observational studies suggest high dietary antioxidant intake reduces AD risk, but of course such studies do not allow definitive cause and effect inferences and are thus prone to confounding [62,63]. Studies associating AD risk with amounts of antioxidant supplement use have not shown a consistent benefit [64]. The most influential antioxidant trial to date is a study of high dose vitamin E on AD progression rates. After manipulating the data to account for baseline inequities in the treatment and placebo groups, it was concluded decline in the 2,000 IU per day vitamin E group was slower than it was in the placebo group [65]. Based mostly on these data, in 2001 the American Academy of Neurology released a dementia management practice parameter paper stating it was moderately convinced vitamin E could “delay the time to clinical worsening” and that 2,000 IU per day of vitamin E “should be considered in an attempt to slow progression of AD” [66]. However, a subsequent meta-analysis of vitamin E clinical trials suggested doses in excess of 400 IU per day could negatively impact overall health [67]. Based on this meta-analysis and the fact that any potential benefit of high dose vitamin E in AD is at best difficult to detect, enthusiasm for this treatment option has waned. More recently it was reported antioxidant supplements may reduce some of the benefits of physical fitness [68], further emphasizing the point that sustained high-dose antioxidant intake may adversely affect health [69]. To sum up existing data on the use of antioxidants in neurodegenerative diseases, some minimal or potential minimal successes are reported but in no case has antioxidant therapy proved transformative.

Minocycline was shown to extend survival in a transgenic mouse model of autosomal dominant ALS (the G93A mouse that expresses a mutant human SOD1 transgene), and this benefit was believed to be mediated by effects on the MPT [70]. Although minocycline benefited the mice, in a placebo controlled study conducted on human sporadic ALS subjects those receiving minocycline actually did worse than those who received the placebo [71].


3. Ongoing and Future Efforts To Develop Neurodegenerative Disease Mitochondrial Medicine
3.1. New drugs for existing targets

Mitochondrial medicine has identified several pharmacologic targets, but manipulating these targets so far has not provided meaningful neurodegenerative disease-modifying treatments. This does not mean the targets are themselves flawed. As with any drug development effort, the form a drug is in when it reaches its target, the amount of drug that reaches the target, whether the drug even reaches its target, how effectively the drug affects the target, and what collateral effects the drug has all require consideration.

As ongoing research advances what is known about a particular target, the approaches used to modify that target also evolve. Antioxidant-based therapeutic development provides a good example of this. There is emerging consensus that free radicals are not uniformly harmful. Numerous variants are recognized, compartmentalization is an issue, and it is clear radicals themselves play important physiologic roles [72,73]. It has accordingly been suggested if neurodegenerative disease oxidative stress is a consequence of mitochondrial dysfunction, it makes sense to direct therapeutic antioxidants to the mitochondrial source [74,75]. This can be accomplished by attaching antioxidants to cationic molecules; doing so allows the antioxidants to concentrate within negatively charged mitochondrial matrices. The most studied mitochondria-targeted antioxidant is MitoQ, which consists of coenzyme Q conjugated to a triphenyl alkyl phosphonium cation [76]. Human phase 2 clinical trials of MitoQ for PD and FA were announced several years ago but results, if any, have not been widely disseminated.

On the other end of the spectrum, drugs not developed as mitochondrial drugs have been recast as such. Dimebon, a drug originally developed as an antihistamine, is a case in point. Early phase clinical evaluations, including a phase 2 human trial, suggest dimebon may benefit AD patients [77]. If correct, it will be necessary to identify the responsible mechanism. Since dimebon has been shown to modify the MPT, a possible mitochondrial mechanism of action has been postulated [78]. It will be interesting to see how dimebon performs in definitive phase 3 testing. Additional studies of how dimebon affects mitochondrial function are underway.

There is of course an alternative explanation to why mitochondrial medicine thus far has not provided effective neurodegenerative mitochondriopathy treatments. It is necessary to consider the possibility that most development efforts targeted phenomena that are perhaps at best downstream of and at worst compensatory adaptations (such as mitochondrial ROS production) to upstream mitochondrial failure or stress. If correct, then new mitochondrial medicine targets are needed.

3.2. Enhancing aerobic metabolism

As far as developing treatments for the neurodegenerative mitochondriopathies goes, this reviewer finds the idea of increasing cell aerobic/anaerobic metabolism ratios particularly intriguing. Cell respiratory capacity declines with age [79], and this decline is exaggerated in neurodegenerative mitochondriopathies [3]. Two non-pharmacologic approaches, exercise and dietary restriction (DR), enhance aerobic infrastructure and have recognized health benefits [80,81,82,83,84,85,86,87]. While these interventions may not uniformly increase oxygen consumption, in at least some instances they do elevate aerobic set points. Delineating mechanisms through which exercise and DR produce their effects could provide a blueprint for how to accomplish this pharmacologically. In general, it appears aerobic metabolism can be enhanced in two ways. A cell can be induced to produce more mitochondria, or its existing mitochondria can be forced to respire more.

3.2.1. With mitochondrial biogenesis

DR, which promotes mitochondrial biogenesis, extends longevity in invertebrate and vertebrate species [88]. There is an apparent relation between life extension and cell respiratory status, as DR can activate the energy supply-sensing enzyme AMP kinase (AMPK) and consistently activates the redox state-sensing deacetylase enzyme SIRT1 [89,90]. These enzymes are suspected to play a role and perhaps even a key role in lifespan extension [91]. Free radicals are most likely also important. One study in C. elegans found antioxidants prevented 2-deoxyglucose, a glycolysis inhibitor that creates a DR-like state, from enhancing longevity [92].

Prolonged exercise also promotes muscle mitochondrial biogenesis. This associates with and probably mediates the endurance benefit that accompanies aerobic training [93]. Aerobic exercise also increases muscle free radical levels, and for this reason some athletes incorporate antioxidant vitamin supplements into their training regimen [94]. As is the case for antioxidants and DR, though, antioxidants seem to adversely affect at least some exercise-associated health benefits [68]. Data further suggest antioxidant supplements may mitigate the mitochondrial biogenesis that typically accompanies fitness training, thereby minimizing the ability of exercise to enhance physical endurance [95].

This review has so far considered antioxidants from the perspective of vitamin supplements such as vitamin E. Antioxidant enzyme systems also impact both cell and organelle free radical levels. Antioxidant enzyme expression is initiated by the same transcription programs that drive mitochondrial biogenesis [96]. In this respect mitochondrial biogenesis and oxidative stress create a feedback loop. If a cell requires more mitochondrial respiration to maintain energy homeostasis the existing mitochondria respire more, mitochondrial superoxide production increases, and oxidative stress signals the nucleus to increase both mitochondrial mass and antioxidant enzyme capacity. This likely explains why exercising muscles show increased free radical production but not increased oxidative damage [97]. It is further important to stress that although some chemicals are billed as antioxidants because they reduce free radical levels, their actual effects on respiratory function may be quite complex.

Resveratrol, a polyphenol compound, provides a good example of this. It is often referred to as an antioxidant, but its ability to reduce oxidative stress may arise indirectly through activation of SIRT1 and, at least in some tissues, mitochondrial biogenesis [98,99,100]. The use of polyphenols for the treatment of neurodegenerative mitochondriopathies is actively being explored.

The thiazolidinedione drugs originally developed to treat type II diabetes have been considered for the treatment of neurodegenerative diseases. The thiazolidinediones, which include rosiglitazone and pioglitazone, are peroxisome proliferator activated receptor γ (PPARG) agonists. They do, however, also affect mitochondrial function and were shown in both in vitro and in vivo settings to enhance mitochondrial biogenesis [101,102,103]. A phase 2 trial of rosiglitazone in AD suggested APOE4-negative subjects might have benefited [104], but a phase 3 trial did not bear this out and efforts to develop thiazolidinediones as AD treatments have apparently been abandoned. Thiazolidinediones, though, poorly penetrate the blood barrier and it is uncertain whether the brain can achieve concentrations that optimally induce mitochondrial biogenesis [102].

3.2.2. Without mitochondrial biogenesis

Enhancing aerobic metabolism without inducing mitochondrial biogenesis may also provide a viable treatment option for the neurodegenerative mitochondriopathies. For example, in tumor cell lines it is certainly possible to increase cell respiration without inducing mitochondrial biogenesis. When human neuroblastoma SH-SY5Y cells are maintained under glucose deprivation conditions mitochondrial respiration increases until the maximum respiratory capacity is reached. Figure 2 shows the oxygen consumption rate (OCR) of SH-SY5Y cells maintained in medium containing 25 mM glucose and medium containing no glucose for 15 hours. Oxygen consumption is greatly increased in the glucose deprived cells. During this time lactate production in the glucose starved cells is, not surprisingly, virtually undetectable. The cells remain viable during this extended period, and presumably divert glutamine contained in the medium to the Krebs cycle and the production of ETC reducing equivalents.

When glucose is injected into the mediums, the starved cells rapidly reduce their OCR below that of the control cells, and increase lactate production above that of the control cells. This indicates the starvation intervention sensitized the cells to glucose consumption. When the glycolysis inhibitor 2-deoxyglucose is next added, the control cells rapidly increase their OCR and decrease their lactate production. With 2-deoxyglucose the control cell OCR actually approximates that of the 15 hour glucose-starved cells, suggesting that although the starved cell OCR was elevated for 15 hours no or little mitochondrial biogenesis occurred.

This experiment provides a cell culture simulation of animal DR. The failure to induce mitochondrial biogenesis in this case is potentially a consequence of the Warburg Effect that applies to tumor cells. The Warburg Effect refers to the tendency of tumor cells to generate their energy anaerobically through glycolysis and lactate formation, and at the expense of oxidative phosphorylation [105,106,107]. This metabolic pattern persists even when adequate oxygen is present. While the results described above may only apply to tumor cells, this experiment does make the point it is probably normal for cells to set their basal respiratory rates below their maximal respiratory capacities. This would provide a respiratory cushion that could be utilized in the event of acute energy crisis. This respiratory reserve could provide a valuable target for mitochondrial medicine, and developing pharmacologic approaches that tap this respiratory reserve could prove useful for the treatment of neurodegenerative mitochondriopathies.

3.3. Opportunities for combination therapy

Optimal neurodegenerative mitochondriopathy therapies will slow or prevent progression by interfering with underlying molecular pathologies and also provide symptomatic benefits. As mitochondrial medicine approaches advance, opportunities for using these approaches with treatments designed to influence other pathologies or specific disease symptoms will arise. For example, if dimebon does benefit AD patients and does so via mitochondrial effects, it will be important to test whether dimebon in conjunction with a cholinesterase inhibitor is more efficacious than using these agents separately.


4. Conclusions

Mitochondrial perturbations are protean in the neurodegenerative diseases. It is reasonable to consider many of these disorders as neurodegenerative mitochondriopathies. The search for effective therapies should include treatments that target mitochondria or pathways affected by mitochondrial function. In pursuing this, whether mitochondrial dysfunction in a particular disease is likely to have an initiating, intermediate, or downstream role in neurodegenerative cascades requires consideration. It is also necessary to take into account whether a pharmacologic intervention is targeting upstream or downstream mitochondrial pathology. Failure to do so could produce therapies that are ineffective or, if they reduce or abolish compensatory physiology, are even harmful.

Mitochondrial medicine thus far has failed to revolutionize the treatment of neurodegenerative diseases, but a better understanding of basic mitochondrial physiology and the role mitochondria actually play in different neurodegenerative diseases will guide more sophisticated drug development efforts. It is worth noting two non-pharmacologic interventions that benefit human health, DR and exercise, increase mitochondrial respiration. The mechanisms that mediate the effects of DR and exercise could provide a blueprint for developing agents that enhance cell respiration. It will be interesting to see whether pharmacologic strategies designed to specifically and powerfully enhance neuron respiration can meaningfully benefit the many individuals that already have or are destined to develop one of these devastating diseases.


Acknowledgements

The data in Figure 2 were generated by Jane Lu.


References and Notes
1.. Swerdlow R.H.. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?Neurobiol. AgingYear: 2007281465148010.1016/j.neurobiolaging.2006.06.02116876913
2.. McKeith I.G.,Galasko D.,Kosaka K.,Perry E.K.,Dickson D.W.,Hansen L.A.,Salmon D.P.,Lowe J.,Mirra S.S.,Byrne E.J.,Lennox G.,Quinn N.P.,Edwardson J.A.,Ince P.G.,Bergeron C.,Burns A.,Miller B.L.,Lovestone S.,Collerton D.,Jansen E.N.,Ballard C.,de Vos R.A.,Wilcock G.K.,Jellinger K.A.,Perry R.H.. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshopNeurologyYear: 199647111311248909416
3.. Swerdlow R.H.. Treating neurodegeneration by modifying mitochondria: Potential solutions to a "complex" problemAntioxid. Redox SignalYear: 200791591160317663643
4.. Swerdlow R.H.. The Neurodegenerative MitochondriopathiesJ. Alzheimers Dis.Year: 2009
5.. Swerdlow R.H.,Kish S.J.. Mitochondria in Alzheimer's diseaseInt. Rev. Neurobiol.Year: 20025334138512512346
6.. Parker W.D. Jr.,Filley C.M.,Parks J.K.. Cytochrome oxidase deficiency in Alzheimer's diseaseNeurologyYear: 199040130213032166249
7.. Swerdlow R.H.. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathiesJ. Neurosci. Res.Year: 2007853416342817243174
8.. Swerdlow R.H.,Parks J.K.,Cassarino D.S.,Maguire D.J.,Maguire R.S.,Bennett J.P. Jr.,Davis R.E.,Parker W.D. Jr.. Cybrids in Alzheimer's disease: A cellular model of the disease?NeurologyYear: 1997499189259339668
9.. Cardoso S.M.,Santana I.,Swerdlow R.H.,Oliveira C.R.. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicityJ. Neurochem.Year: 2004891417142615189344
10.. Hirai K.,Aliev G.,Nunomura A.,Fujioka H.,Russell R.L.,Atwood C.S.,Johnson A.B.,Kress Y.,Vinters H.V.,Tabaton M.,Shimohama S.,Cash A.D.,Siedlak S.L.,Harris P.L.,Jones P.K.,Petersen R.B.,Perry G.,Smith M.A.. Mitochondrial abnormalities in Alzheimer's diseaseJ. Neurosci.Year: 2001213017302311312286
11.. Wang X.,Su B.,Lee H.G.,Li X.,Perry G.,Smith M.A.,Zhu X.. Impaired balance of mitochondrial fission and fusion in Alzheimer's diseaseJ. Neurosci.Year: 2009299090910319605646
12.. Reddy P.H.,McWeeney S.,Park B.S.,Manczak M.,Gutala R.V.,Partovi D.,Jung Y.,Yau V.,Searles R.,Mori M.,Quinn J.. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's diseaseHum. Mol. Genet.Year: 2004131225124015115763
13.. Yao J.,Irwin R.W.,Zhao L.,Nilsen J.,Hamilton R.T.,Brinton R.D.. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's diseaseProc. Natl. Acad. Sci. USAYear: 2009106146701467519667196
14.. Du H.,Guo L.,Fang F.,Chen D.,Sosunov A.A.,McKhann G.M.,Yan Y.,Wang C.,Zhang H.,Molkentin J.D.,Gunn-Moore F.J.,Vonsattel J.P.,Arancio O.,Chen J.X.,Yan S.D.. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's diseaseNat. Med.Year: 2008141097110518806802
15.. Lustbader J.W.,Cirilli M.,Lin C.,Xu H.W.,Takuma K.,Wang N.,Caspersen C.,Chen X.,Pollak S.,Chaney M.,Trinchese F.,Liu S.,Gunn-Moore F.,Lue L.F.,Walker D.G.,Kuppusamy P.,Zewier Z.L.,Arancio O.,Stern D.,Yan S.S.,Wu H.. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's diseaseScienceYear: 200430444845215087549
16.. Anandatheerthavarada H.K.,Devi L.. Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's diseaseNeuroscientistYear: 20071362663817911214
17.. Caspersen C.,Wang N.,Yao J.,Sosunov A.,Chen X.,Lustbader J.W.,Xu H.W.,Stern D.,McKhann G.,Yan S.D.. Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer's diseaseFASEB J.Year: 2005192040204116210396
18.. Devi L.,Prabhu B.M.,Galati D.F.,Avadhani N.G.,Anandatheerthavarada H.K.. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunctionJ. Neurosci.Year: 2006269057906816943564
19.. Gabuzda D.,Busciglio J.,Chen L.B.,Matsudaira P.,Yankner B.A.. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivativeJ. Biol. Chem.Year: 199426913623136288175797
20.. Khan S.M.,Cassarino D.S.,Abramova N.N.,Keeney P.M.,Borland M.K.,Trimmer P.A.,Krebs C.T.,Bennett J.C.,Parks J.K.,Swerdlow R.H.,Parker W.D. Jr.,Bennett J.P. Jr.. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathwaysAnn. Neurol.Year: 20004814815510.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-710939564
21.. Swerdlow R.H.,Khan S.M.. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's diseaseMed. HypothesesYear: 20046382015193340
22.. Swerdlow R.H.,Khan S.M.. The Alzheimer's disease mitochondrial cascade hypothesis: An updateExp. Neurol.Year: 200921830831519416677
23.. Parker W.D. Jr.,Boyson S.J.,Parks J.K.. Abnormalities of the electron transport chain in idiopathic Parkinson's diseaseAnn. Neurol.Year: 1989267197232557792
24.. Arduino D.M.,Esteves A.R.,Oliveira C.R.,Cardoso S.M.. Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinson's DiseaseCNS Neurol. Disord. Drug TargetsYear: 2009
25.. Betarbet R.,Sherer T.B.,MacKenzie G.,Garcia-Osuna M.,Panov A.V.,Greenamyre J.T.. Chronic systemic pesticide exposure reproduces features of Parkinson's diseaseNat. Neurosci.Year: 200031301130611100151
26.. Langston J.W.,Ballard P.,Tetrud J.W.,Irwin I.. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesisScienceYear: 19832199799806823561
27.. Swerdlow R.H.,Parks J.K.,Miller S.W.,Tuttle J.B.,Trimmer P.A.,Sheehan J.P.,Bennett J.P. Jr.,Davis R.E.,Parker W.D. Jr.. Origin and functional consequences of the complex I defect in Parkinson's diseaseAnn. Neurol.Year: 19964066367110.1002/ana.4104004178871587
28.. Esteves A.R.,Domingues A.F.,Ferreira I.L.,Januario C.,Swerdlow R.H.,Oliveira C.R.,Cardoso S.M.. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear backgroundMitochondrionYear: 2008821922818495557
29.. Esteves A.R.,Arduino D.M.,Swerdlow R.H.,Oliveira C.R.,Cardoso S.M.. Oxidative Stress involvement in alpha-synuclein oligomerization in Parkinsons disease cybridsAntioxid. Redox SignalYear: 2008
30.. Bender A.,Krishnan K.J.,Morris C.M.,Taylor G.A.,Reeve A.K.,Perry R.H.,Jaros E.,Hersheson J.S.,Betts J.,Klopstock T.,Taylor R.W.,Turnbull D.M.. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson diseaseNat. Genet.Year: 20063851551716604074
31.. Kraytsberg Y.,Kudryavtseva E.,McKee A.C.,Geula C.,Kowall N.W.,Khrapko K.. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neuronsNat. Genet.Year: 20063851852016604072
32.. Parker W.D. Jr.,Parks J.K.. Mitochondrial ND5 mutations in idiopathic Parkinson's diseaseBiochem. Biophys. Res. Commun.Year: 200532666766915596151
33.. Smigrodzki R.,Parks J.,Parker W.D.. High frequency of mitochondrial complex I mutations in Parkinson's disease and agingNeurobiol. AgingYear: 2004251273128115465623
34.. Beal M.F.. Aging, energy, and oxidative stress in neurodegenerative diseasesAnn. Neurol.Year: 19953835736610.1002/ana.4103803047668820
35.. Bueler H.. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's diseaseExp. Neurol.Year: 200921823524619303005
36.. Swerdlow R.H.,Parks J.K.,Cassarino D.S.,Trimmer P.A.,Miller S.W.,Maguire D.J.,Sheehan J.P.,Maguire R.S.,Pattee G.,Juel V.C.,Phillips L.H.,Tuttle J.B.,Bennett J.P. Jr.,Davis R.E.,Parker W.D. Jr.. Mitochondria in sporadic amyotrophic lateral sclerosisExp. Neurol.Year: 199815313514210.1006/exnr.1998.68669743575
37.. Swerdlow R.H.,Parks J.K.,Pattee G.,Parker W.D. Jr.. Role of mitochondria in amyotrophic lateral sclerosisAmyotroph. Lateral Scler. Other Motor Neuron Disord.Year: 2000118519011464951
38.. Albers D.S.,Swerdlow R.H.,Manfredi G.,Gajewski C.,Yang L.,Parker W.D. Jr.,Beal M.F.. Further evidence for mitochondrial dysfunction in progressive supranuclear palsyExp. Neurol.Year: 200116819619811170735
39.. Swerdlow R.H.,Golbe L.I.,Parks J.K.,Cassarino D.S.,Binder D.R.,Grawey A.E.,Litvan I.,Bennett J.P. Jr.,Wooten G.F.,Parker W.D.. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsyJ. Neurochem.Year: 2000751681168410987850
40.. Browne S.E.,Beal M.F.. The energetics of Huntington's diseaseNeurochem. Res.Year: 20042953154615038601
41.. Cui L.,Jeong H.,Borovecki F.,Parkhurst C.N.,Tanese N.,Krainc D.. Transcriptional repression of PGC-alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegenerationCellYear: 2006127596917018277
42.. Panov A.V.,Gutekunst C.A.,Leavitt B.R.,Hayden M.R.,Burke J.R.,Strittmatter W.J.,Greenamyre J.T.. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutaminesNat. Neurosci.Year: 2002573173612089530
43.. Koutnikova H.,Campuzano V.,Foury F.,Dolle P.,Cazzalini O.,Koenig M.. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxinNat. Genet.Year: 1997163453519241270
44.. Pandolfo M.. Friedreich ataxiaArch. Neurol.Year: 2008651296130318852343
45.. Luft R.. The development of mitochondrial medicineProc. Natl. Acad. Sci. U. S. A.Year: 199491873187388090715
46.. Mattson M.P.. Apoptosis in neurodegenerative disordersNat. Rev. Mol. Cell Biol.Year: 2000112012911253364
47.. Aliev G.,Liu J.,Shenk J.C.,Fischbach K.,Pacheco G.J.,Chen S.G.,Obrenovich M.E.,Ward W.F.,Richardson A.G.,Smith M.A.,Gasimov E.,Perry G.,Ames B.N.. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged ratsJ. Cell Mol. Med.Year: 20091332033318373733
48.. Rosca M.G.,Lemieux H.,Hoppel C.L.. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator?Adv. Drug Deliv. Rev.Year: 2009
49.. Veech R.L.,Chance B.,Kashiwaya Y.,Lardy H.A.,Cahill G.F. Jr.. Ketone bodies, potential therapeutic usesIUBMB LifeYear: 20015124124711569918
50.. Adhihetty P.J.,Beal M.F.. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseasesNeuromolecular Med.Year: 20081027529019005780
51.. Saelens X.,Festjens N.,Vande Walle L.,van Gurp M.,van Loo G.,Vandenabeele P.. Toxic proteins released from mitochondria in cell deathOncogeneYear: 2004232861287415077149
52.. Crompton M.,Virji S.,Doyle V.,Johnson N.,Ward J.M.. The mitochondrial permeability transition poreBiochem. Soc. Symp.Year: 19996616717910989666
53.. Lemasters J.J.,Theruvath T.P.,Zhong Z.,Nieminen A.L.. Mitochondrial calcium and the permeability transition in cell deathBiochim. Biophys. ActaYear: 200917871395140119576166
54.. Haller R.G.,Vissing J.. Drilling for energy in mitochondrial diseaseArch. Neurol.Year: 20096693193219667212
55.. Mestre T.,Ferreira J.,Coelho M.M.,Rosa M.,Sampaio C.. Therapeutic interventions for disease progression in Huntington's diseaseCochrane Database Syst. Rev.Year: 2009CD00645519588392
56.. Swerdlow R.,Marcus D.M.,Landman J.,Harooni M.,Freedman M.L.. Brain glucose and ketone body metabolism in patients with Alzheimer's diseaseClin. Res.Year: 198937461A
57.. Henderson S.T.,Vogel J.L.,Barr L.J.,Garvin F.,Jones J.J.,Costantini L.C.. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trialNutr. Metab. (Lond)Year: 200963119664276
58.. Shults C.W.,Oakes D.,Kieburtz K.,Beal M.F.,Haas R.,Plumb S.,Juncos J.L.,Nutt J.,Shoulson I.,Carter J.,Kompoliti K.,Perlmutter J.S.,Reich S.,Stern M.,Watts R.L.,Kurlan R.,Molho E.,Harrison M.,Lew M.. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional declineArch. Neurol.Year: 2002591541155012374491
59.. Kearney M.,Orrell R.W.,Fahey M.,Pandolfo M.. Antioxidants and other pharmacological treatments for Friedreich ataxiaCochrane Database Syst. Rev.Year: 2009CD00779119821439
60.. Mariotti C.,Solari A.,Torta D.,Marano L.,Fiorentini C.,Di Donato S.. Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trialNeurologyYear: 2003601676167912771264
61.. Stamelou M.,Reuss A.,Pilatus U.,Magerkurth J.,Niklowitz P.,Eggert K.M.,Krisp A.,Menke T.,Schade-Brittinger C.,Oertel W.H.,Hoglinger G.U.. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trialMov. Disord.Year: 20082394294918464278
62.. Engelhart M.J.,Geerlings M.I.,Ruitenberg A.,van Swieten J.C.,Hofman A.,Witteman J.C.,Breteler M.M.. Dietary intake of antioxidants and risk of Alzheimer diseaseJAMAYear: 20022873223322912076218
63.. Engelhart M.J.,Ruitenberg A.,Meijer J.,Kiliaan A.,van Swieten J.C.,Hofman A.,Witteman J.C.,Breteler M.M.. Plasma levels of antioxidants are not associated with Alzheimer's disease or cognitive declineDement. Geriatr. Cogn. Disord.Year: 20051913413915627760
64.. Boothby L.A.,Doering P.L.. Vitamin C and vitamin E for Alzheimer's diseaseAnn. Pharmacother.Year: 2005392073208016227450
65.. Sano M.,Ernesto C.,Thomas R.G.,Klauber M.R.,Schafer K.,Grundman M.,Woodbury P.,Growdon J.,Cotman C.W.,Pfeiffer E.,Schneider L.S.,Thal L.J.. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative StudyN. Engl. J. Med.Year: 1997336121612229110909
66.. Doody R.S.,Stevens J.C.,Beck C.,Dubinsky R.M.,Kaye J.A.,Gwyther L.,Mohs R.C.,Thal L.J.,Whitehouse P.J.,DeKosky S.T.,Cummings J.L.. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurologyYear: 2001561154116611342679
67.. Miller E.R. 3rd,Pastor-Barriuso R.,Dalal D.,Riemersma R.A.,Appel L.J.,Guallar E.. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortalityAnn. Intern. Med.Year: 2005142374615537682
68.. Ristow M.,Zarse K.,Oberbach A.,Kloting N.,Birringer M.,Kiehntopf M.,Stumvoll M.,Kahn C.R.,Bluher M.. Antioxidants prevent health-promoting effects of physical exercise in humansProc. Natl. Acad. Sci. U. S. A.Year: 20091068665867019433800
69.. Bjelakovic G.,Nikolova D.,Gluud L.L.,Simonetti R.G.,Gluud C.. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysisJAMAYear: 200729784285717327526
70.. Zhu S.,Stavrovskaya I.G.,Drozda M.,Kim B.Y.,Ona V.,Li M.,Sarang S.,Liu A.S.,Hartley D.M.,Wu D.C.,Gullans S.,Ferrante R.J.,Przedborski S.,Kristal B.S.,Friedlander R.M.. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in miceNatureYear: 2002417747811986668
71.. Gordon P.H.,Moore D.H.,Miller R.G.,Florence J.M.,Verheijde J.L.,Doorish C.,Hilton J.F.,Spitalny G.M.,MacArthur R.B.,Mitsumoto H.,Neville H.E.,Boylan K.,Mozaffar T.,Belsh J.M.,Ravits J.,Bedlack R.S.,Graves M.C.,McCluskey L.F.,Barohn R.J.,Tandan R.. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trialLancet Neurol.Year: 200761045105317980667
72.. Finkel T.. Reactive oxygen species and signal transductionIUBMB LifeYear: 2001523611795590
73.. Finkel T.. Oxidant signals and oxidative stressCurr. Opin. Cell Biol.Year: 20031524725412648682
74.. Armstrong J.S.. Mitochondrial medicine: Pharmacological targeting of mitochondria in diseaseBr. J. Pharmacol.Year: 20071511154116517519949
75.. Reddy P.H.. Mitochondrial oxidative damage in aging and Alzheimer's disease: Implications for mitochondrially targeted antioxidant therapeuticsJ. Biomed. Biotechnol.Year: 200620063137217047303
76.. Kelso G.F.,Porteous C.M.,Coulter C.V.,Hughes G.,Porteous W.K.,Ledgerwood E.C.,Smith R.A.,Murphy M.P.. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic propertiesJ. Biol. Chem.Year: 20012764588459611092892
77.. Doody R.S.,Gavrilova S.I.,Sano M.,Thomas R.G.,Aisen P.S.,Bachurin S.O.,Seely L.,Hung D.. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled studyLancetYear: 200837220721518640457
78.. Bachurin S.O.,Shevtsova E.P.,Kireeva E.G.,Oxenkrug G.F.,Sablin S.O.. Mitochondria as a target for neurotoxins and neuroprotective agentsAnn. NY Acad. Sci.Year: 2003993334344 discussion 345-339. 12853325
79.. Navarro A.,Boveris A.. The mitochondrial energy transduction system and the aging processAm. J. Physiol. Cell Physiol.Year: 2007292C670C68617020935
80.. Boveris A.,Navarro A.. Systemic and mitochondrial adaptive responses to moderate exercise in rodentsFree Radic. Biol. Med.Year: 20084422422918191758
81.. Civitarese A.E.,Smith S.R.,Ravussin E.. Diet, energy metabolism and mitochondrial biogenesisCurr. Opin. Clin. Nutr. Metab. CareYear: 20071067968718089947
82.. Fernstrom M.,Tonkonogi M.,Sahlin K.. Effects of acute and chronic endurance exercise on mitochondrial uncoupling in human skeletal muscleJ. Physiol.Year: 200455475576314634202
83.. Hepple R.T.. Why eating less keeps mitochondria working in aged skeletal muscleExerc. Sport Sci. Rev.Year: 200937232819098521
84.. Holloszy J.O.. Adaptation of skeletal muscle to endurance exerciseMed. Sci. SportsYear: 19757155164173969
85.. Hood D.A.. Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscleAppl. Physiol. Nutr. Metab.Year: 20093446547219448716
86.. Hoppeler H.,Fluck M.. Plasticity of skeletal muscle mitochondria: Structure and functionMed. Sci. Sports Exerc.Year: 2003359510412544642
87.. Lambert A.J.,Wang B.,Yardley J.,Edwards J.,Merry B.J.. The effect of aging and caloric restriction on mitochondrial protein density and oxygen consumptionExp. Gerontol.Year: 20043928929515036388
88.. Weindruch R.,Sohal R.S.. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and agingN. Engl. J. Med.Year: 199733798699410.1056/NEJM1997100233714079309105
89.. Greer E.L.,Brunet A.. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegansAging CellYear: 2009811312710.1111/j.1474-9726.2009.00459.x19239417
90.. Haigis M.C.,Guarente L.P.. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restrictionGenes Dev.Year: 2006202913292110.1101/gad.146750617079682
91.. Spindler S.R.. Biological effects of calorie restriction: From soup to nutsAgeing Res. Rev.Year: 2009
92.. Schulz T.J.,Zarse K.,Voigt A.,Urban N.,Birringer M.,Ristow M.. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stressCell Metab.Year: 2007628029317908557
93.. Norrbom J.,S E.W.,Gustafsson T.,Rundqvist H.,Jansson E.,Sundberg C.. Training response of mitochondrial transcription factors in human skeletal muscleActa Physiol. (Oxf)2009
94.. McGinley C.,Shafat A.,Donnelly A.E.. Does Antioxidant Vitamin Supplementation Protect against Muscle Damage?Sports Med.Year: 2009391011103210.2165/11317890-000000000-0000019902983
95.. Gomez-Cabrera M.C.,Domenech E.,Romagnoli M.,Arduini A.,Borras C.,Pallardo F.V.,Sastre J.,Vina J.. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performanceAm. J. Clin. Nutr.Year: 20088714214918175748
96.. Onyango I.G.,Lu J.,Rodova M.,Lezi E.,Crafter A.B.,Swerdlow R.H.. Regulation of neuron mitochondrial biogenesis and relevance to brain healthBiochim. Biophys. ActaYear: 2009
97.. Ji L.L.,Gomez-Cabrera M.C.,Vina J.. Exercise and hormesis: Activation of cellular antioxidant signaling pathwayAnn. N. Y. Acad. Sci.Year: 2006106742543516804022
98.. Anekonda T.S.,Reddy P.H.. Neuronal protection by sirtuins in Alzheimer's diseaseJ. Neurochem.Year: 20069630531316219030
99.. Guarente L.. Sirtuins in aging and diseaseCold Spring Harb. Symp. Quant. Biol.Year: 20077248348818419308
100.. Harikumar K.B.,Aggarwal B.B.. Resveratrol: A multitargeted agent for age-associated chronic diseasesCell CycleYear: 200871020103518414053
101.. Bogacka I.,Xie H.,Bray G.A.,Smith S.R.. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivoDiabetesYear: 2005541392139915855325
102.. Ghosh S.,Patel N.,Rahn D.,McAllister J.,Sadeghi S.,Horwitz G.,Berry D.,Wang K.X.,Swerdlow R.H.. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cellsMol. Pharmacol.Year: 2007711695170217387142
103.. Strum J.C.,Shehee R.,Virley D.,Richardson J.,Mattie M.,Selley P.,Ghosh S.,Nock C.,Saunders A.,Roses A.. Rosiglitazone induces mitochondrial biogenesis in mouse brainJ. Alzheimers Dis.Year: 200711455117361034
104.. Risner M.E.,Saunders A.M.,Altman J.F.,Ormandy G.C.,Craft S.,Foley I.M.,Zvartau-Hind M.E.,Hosford D.A.,Roses A.D.. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's diseasePharmacogenomics J.Year: 2006624625416446752
105.. Ferguson E.C.,Rathmell J.C.. New roles for pyruvate kinase M2: Working out the Warburg effectTrends Biochem. Sci.Year: 20083335936218603432
106.. Feron O.. Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cellsRadiother. Oncol.Year: 20099232933319604589
107.. Vander Heiden M.G.,Cantley L.C.,Thompson C.B.. Understanding the Warburg effect: The metabolic requirements of cell proliferationScienceYear: 20093241029103319460998

Figures

[Figure ID: pharmaceuticals-02-00150-f001]
Figure 1 

An integrated view of pathways involved in cell energy production.



[Figure ID: pharmaceuticals-02-00150-f002]
Figure 2 

In human neuroblastoma cells, glucose starvation increases mitochondrial respiration without inducing obvious mitochondrial biogenesis. The data in this figure were produced using an XF24 Flux Analzyer (Seahorse Biosciences). At the start of the experiment SH-SY5Y cells were maintained in either normal DMEM medium (control cells) or in DMEM containing no glucose (starved cells); at the time these measurements were taken the starved cell had been without glucose for 15 hours. Glucose starved cell metabolic physiology is indicated by orange lines, and control cell metabolic physiology is indicated by blue lines. Panel (A) shows the oxygen consumption rates (OCR) of cells maintained under the two conditions, and panel (B) shows the extracellular acidification rate (ECAR) that is mostly due to lactate excretion. After baseline OCR and ECAR values are established, glucose was injected in the mediums, and this had a profound effect on the starved but not the control cells. The glycolysis inhibitor 2-deoxyglucose was next injected, which rapidly increased the control cell OCR to the level it was in the 15 hour starved cells. This was followed by injection of the ATP synthase inhibitor oligomycin, which terminates coupled mitochondrial respiration. Lastly, the complex I and III inhibitors rotenone and myxothiazol were used to stop the residual uncoupled mitochondrial respiration, so only non-mitochondrial oxygen consumption remains. After oligomycin and again after rotenone and myxothiazol the OCR values for both the control and starved cells were similar, indicating in the experiment starved and control cell numbers were equivalent. Additional details pertaining to this experiment are provided in the text. 2 DG=2 deoxyglucose; oligo=oligomycin; rot=rotenone; myx=myxothiazol.



Article Categories:
  • Review

Keywords: mitochondria, mitochondrial biogenesis, mitochondriopathies, neuro-degenerative diseases, oxidative stress.

Previous Document:  Survival of patients with ovarian cancer in central and northern Denmark, 1998-2009.
Next Document:  Spinal intramedullary cysticercosis: a case report and literature review.